Amphastar Pharmaceuticals, Inc. (AMPH): Shareholders' Equity
$788.80M
As of 2025-12-31
$768.16M
As of 2026-06-30
+14.3%
3-year compound annual growth
+11.9%
5-year compound annual growth
| Period ended | Shareholders' Equity | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $788.80M | +7.7% | 2026-02-26, Balance as of period end |
| 2024-12-31 | $732.30M | +14.5% | 2026-02-26, Balance as of period end |
| 2023-12-31 | $639.42M | +21.0% | 2026-02-26, Balance as of period end |
| 2022-12-31 | $528.66M | +18.7% | 2025-03-03, Balance as of period end |
| 2021-12-31 | $445.52M | -0.7% | 2024-02-29, Balance as of period end |
| 2020-12-31 | $448.72M | +5.0% | 2023-03-01, Balance as of period end |
| 2019-12-31 | $427.53M | +17.3% | 2022-03-11, Balance as of period end |
| 2018-12-31 | $364.36M | +9.2% | 2021-03-15, Balance as of period end |
| 2017-12-31 | $333.74M | +2.2% | 2020-03-16, Balance as of period end |
| 2016-12-31 | $326.52M | n/a | 2019-03-15, Balance as of period end |
Shareholders' Equity at similar companies
| Company | Year ended | Shareholders' Equity | Change YoY |
|---|---|---|---|
| Amphastar Pharmaceuticals, Inc. (AMPH) | 2025-12-31 | $788.80M | +7.7% |
| Supernus Pharmaceuticals, Inc. (SUPN) | 2025-12-31 | $1.06B | +2.5% |
| Pacira BioSciences, Inc. (PCRX) | 2025-12-31 | $693.11M | -11.0% |
| Emergent BioSolutions Inc. (EBS) | 2025-12-31 | $522.60M | +8.2% |
| Corcept Therapeutics Inc (CORT) | 2025-12-31 | $647.80M | -4.7% |
| Kiniksa Pharmaceuticals International, plc (KNSA) | 2025-12-31 | $567.61M | +29.5% |
| Ultragenyx Pharmaceutical Inc. (RARE) | 2025-12-31 | -$80.00M | n/m |
| Collegium Pharmaceutical, Inc (COLL) | 2025-12-31 | $301.68M | +31.8% |
| Axsome Therapeutics, Inc. (AXSM) | 2025-12-31 | $88.30M | +54.9% |
Compare AMPH, SUPN, PCRX, EBS side by side · Screen every company in Pharmaceutical Preparations ↗